TABLE 1.
MICs of drug substances against 235 E. faecalis strains
| E. faecalis strains (no. of strains) | Drug | MIC (μg/ml)
|
||
|---|---|---|---|---|
| Range | 50% | 90% | ||
| Gentamicin susceptible (164) | HMR 3647 | ≤0.008–16 | 0.03 | 4.0 |
| Erythromycin A | 0.25–>32.0 | 2.0 | >32.0 | |
| Azithromycin | 0.5–>32.0 | 8.0 | >32.0 | |
| Clarithromycin | 0.125–>32.0 | 2.0 | >32.0 | |
| Roxithromycin | 0.5–>32.0 | 16.0 | >32.0 | |
| Clindamycin | 4.0–>32.0 | 32.0 | >32.0 | |
| Quinupristin-dalfopristin | ≤1.0–32.0 | 8.0 | 8.0 | |
| High-level gentamicin resistanta (71) | HMR 3647 | ≤0.008–16.0 | 1.0 | 8.0 |
| Erythromycin A | 0.5–>32.0 | >32.0 | >32.0 | |
| Azithromycin | 2.0–>32.0 | >32.0 | >32.0 | |
| Clarithromycin | 0.25–>32.0 | >32.0 | >32.0 | |
| Roxithromycin | 4.0–>32.0 | >32.0 | >32.0 | |
| Clindamycin | 16.0–>32.0 | >32.0 | >32.0 | |
| Quinupristin-dalfopristin | 2.0–32.0 | 8.0 | 16.0 | |
| β-Lactamase producing (10) | HMR 3647 | 0.016–16.0 | 8.0 | 16.0 |
| Erythromycin A | 0.5–>32.0 | >32.0 | >32.0 | |
| Azithromycin | 2.0–>32.0 | >32.0 | >32.0 | |
| Clarithromycin | 0.25–>32.0 | >32.0 | >32.0 | |
| Roxithromycin | 4.0–>32.0 | >32.0 | >32.0 | |
| Clindamycin | 16.0–>32.0 | >32.0 | >32.0 | |
| Quinupristin-dalfopristin | 4.0–32.0 | 16.0 | 16.0 | |
| Erythromycin A susceptibleb and moderately clindamycin susceptibled (26) | HMR 3647 | ≤0.008–0.06 | 0.03 | 0.06 |
| Erythromycin A | 0.25–0.5 | 0.5 | 0.5 | |
| Azithromycin | 0.5–16.0 | 2.0 | 2.0 | |
| Clarithromycin | 0.125–0.5 | 0.25 | 0.5 | |
| Roxithromycin | 0.5–8.0 | 2.0 | 4.0 | |
| Clindamycin | 8.0–32.0 | 32.0 | 32.0 | |
| Quinupristin-dalfopristin | 2.0–8.0 | 8.0 | 8.0 | |
| Erythromycin A resistantc and clindamycin resistante (107) | HMR 3647 | 0.03–16.0 | 2.0 | 8.0 |
| Erythromycin A | 8.0–>32.0 | >32.0 | >32.0 | |
| Azithromycin | 8.0–>32.0 | >32.0 | >32.0 | |
| Clarithromycin | 2.0–>32.0 | >32.0 | >32.0 | |
| Roxithromycin | 16.0–>32.0 | >32.0 | >32.0 | |
| Clindamycin | >32.0 | >32.0 | >32.0 | |
| Quinupristin-dalfopristin | 1.0–32.0 | 8.0 | 16.0 | |
| Vancomycin resistantf (13) | HMR 3647 | 0.06–16.0 | 2.0 | 8.0 |
| Erythromycin A | 2.0–>32.0 | >32.0 | >32.0 | |
| Azithromycin | 8.0–>32.0 | >32.0 | >32.0 | |
| Clarithromycin | 1.0–>32.0 | >32.0 | >32.0 | |
| Roxithromycin | 8.0–>32.0 | >32.0 | >32.0 | |
| Clindamycin | 32.0–>32.0 | >32.0 | >32.0 | |
| Quinupristin-dalfopristin | 4.0–16.0 | 8.0 | 16.0 | |
| All strains (235) | HMR 3647 | ≤0.008–16.0 | 0.06 | 4.0 |
| Erythromycin A | 0.25–>32.0 | 4.0 | >32.0 | |
| Azithromycin | 0.5–>32.0 | 16.0 | >32.0 | |
| Clarithromycin | 0.125–>32.0 | 2.0 | >32.0 | |
| Roxithromycin | 0.5–>32.0 | 32.0 | >32.0 | |
| Clindamycin | 8.0–>32.0 | 32.0 | >32.0 | |
| Quinupristin-dalfopristin | 1.0–32.0 | 8.0 | 16.0 | |
a
>500 μg/ml.
b
≤0.5 μg/ml.
c
≥8.0 μg/ml.
d
8.0 to 32.0 μg/ml.
e
≥64.0 μg/ml.
f
≥16.0 μg/ml. Nine strains had the VanA phenotype, and four strains had the VanB phenotype.